Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Dec 1;44(12):2177-2184.
doi: 10.1097/IAE.0000000000004244.

GOOD INITIAL VISUAL ACUITY IN PATIENTS WITH MACULAR EDEMA DUE TO RETINAL VEIN OCCLUSION: Management and Outcomes

Nir Gomel  1 , Rossella D'Aloisio  2 , Aya Wattad  1 , Rodolfo Mastropasqua  3 , Federico Formenti  2 , Anat Loewenstein  1 , Matias Iglicki  4 , Dinah Zur  1
Affiliations
Multicenter Study

GOOD INITIAL VISUAL ACUITY IN PATIENTS WITH MACULAR EDEMA DUE TO RETINAL VEIN OCCLUSION: Management and Outcomes

Nir Gomel et al. Retina. .

Abstract

Purpose: The approach to managing patients with retinal vein occlusion and cystoid macular edema (CME) with good initial visual acuity better than 6/12 has not been investigated. This study aimed to evaluate functional and anatomical outcomes of intravitreal treatment and observation in patients with CME because of retinal vein occlusion, who presented with good initial visual acuity.

Methods: Multicenter retrospective cohort study. Seventy-nine eyes of 79 patients with CME secondary to retinal vein occlusion and initial visual acuity better than 6/12, either treated with antivascular endothelial growth factor therapy or observed. Clinical parameters and optical coherence tomography measures were recorded. Main Outcome Measure: Proportion of patients losing ≥1 line of visual acuity at 12 months. Secondary outcomes: visual and anatomical results at 12 months and 24 months, and correlation between number of injections and visual acuity outcomes.

Results: Fifty-three percent of patients maintained visual acuity at month 12. Visual acuity of 6/6 to 6/7.5 was maintained in 59% and 57% at 12 months and 24 months, respectively. At 24 months, the number of antivascular endothelial growth factor injections was strongly correlated with visual acuity among patients with branch retinal vein occlusion and central retinal vein occlusion.

Conclusion: This study marks the first exploration of patients with retinal vein occlusion and initial visual acuity better than 6/12, indicating that most patients sustained good visual acuity, and antivascular endothelial growth factor treatment maintained and improved visual acuity.

PubMed Disclaimer

References

    1. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000;98:133–143.
    1. Scott IU, VanVeldhuisen PC, Ip MS, et al. Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion: the SCORE2 randomized clinical trial. JAMA 2017;317:2072–2087.
    1. Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 2012;119:802–809.
    1. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1124–1133.e1.
    1. Brown DM, Heier JS, Clark WL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 2013;155:429–437.e7.

Publication types

MeSH terms

LinkOut - more resources